﻿<?xml version="1.0" encoding="utf-8"?><rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/"><channel><title>Cision News</title><link>https://news.cision.com</link><description>Cision is the leading global provider of media research, distribution, monitoring and evaluation services. With over 40 locations throughout the world, Cision provides the insight, expertise and intelligence that improve performance and build reputations.</description><pubDate>Wed, 10 Jun 2026 02:03:29 GMT</pubDate><image><title>Cision News</title><width>146</width><height>60</height><link>https://news.cision.com</link><url>https://news.cision.com/Content/img/news-logo.png</url></image><item><title>GSK AND TANABE TO COLLABORATE ON DEVELOPMENT AND COMMERCIALISATI</title><link>http://news.cision.com/glaxosmithkline-plc/r/gsk-and-tanabe-to-collaborate-on-development-and-commercialisati,e47732</link><guid isPermaLink="false">cision45597</guid><description><![CDATA[GSK and Tanabe To Collaborate On Development and Commercialisation Of Preclinical Products Tanabe Seiyaku Co, Ltd. and GlaxoSmithKline plc (GSK) today announce that they have signed a letter of intent to enter into a broad-ranging global collaboration on the research, development and commercialisation of a series of compounds from Tanabe, which covers a range of potential therapeutic areas, including psychiatry, neurology, urology and diabetes. The terms of the Agreement remain to be finalised, but under the letter of intent, GSK will gain access to pre-clinical compounds, with the]]></description><pubDate>Tue, 11 Sep 2001 09:14:20 GMT</pubDate></item></channel></rss>